Lispro insulin-induced lipoatrophy: A new case

Pediatric Diabetes

Volumn 8, Issue 6, 2007, Pages 393-396

  Al khenaizan, Sultan ^a   Al Thubaiti, Mastour ^a   Al Alwan, Ibrahim ^a  

^a KING FAHAD NATIONAL GUARD HOSPITAL   (Saudi Arabia)

Author keywords

Diabetes; Insulin; Lipoatrophy; Lipodystrophy

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; INSULIN; INSULIN LISPRO; ISOPHANE INSULIN; NEUTRAL INSULIN;

ACANTHOSIS NIGRICANS; ANTIBODY BLOOD LEVEL; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; LIPOATROPHY; PRESCHOOL CHILD; PRIORITY JOURNAL; SKIN EXAMINATION;

CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; LIPODYSTROPHY;

EID: 36448947997     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2007.00296.x     Document Type: Article

References (41)

1. Richardson T, Kerr D. Skin-related complications of insulin therapy: epidemiology and emerging management strategies. Am J Clin Dermatol 2003: 4: 661-667.
2. Kumar O, Miller L, Mehtalia S. Use of dexamethasone in treatment of insulin lipoatrophy. Diabetes 1977: 26: 296-299.
3. Wilson RM, Douglas CA, Tattersall RB, Reeves WG. Immunogenicity of highly purified bovine insulin: A comparison with conventional bovine and highly purified human insulins. Diabetologia 1985: 28: 667-670.
4. Mc Nally PG, Jowett NI, Kurinczuk JJ, Peck RW, Hearnshaw JR. Lipohypertrophy and lipoatrophy complicating treatment with highly purified bovine and porcine insulins. Postgrad Med J 1988: 64: 850-853.
5. Murao S, Hirata K, Ishida T, Takahara J. Lipoatrophy induced by recombinant human insulin injection. Intern Med 1998: 37: 1031-1033.
6. Mu L, Goldman JM. Human recombinant DNA insulin-induced lipoatrophy in a patient with type 2 diabetes mellitus. Endocr Pract 2000: 6: 151-152.
7. Paley RG. Lipodystrophy following insulin injections. Metabolism 1953: 2: 201-210.
8. Cochrane G, Dixon FJ. Immune complex injury. In: S amrer M, ed. Immunological Diseases. Boston: Little Brown, 1978: 210-229.
9. Reeves WG, Allen BR, Tattersal RB. Insulin-induced lipoatrophy: Evidence for an immune pathogenesis. Br Med J 1980: 280: 1500-1503.
10. Valenta LJ, Elias AN. Insulin-induced lipodystrophy in diabetic patients resolved by treatment with human insulin. Ann Intern Med 1985: 102: 790-791.
11. Griffin ME, Feder A, Tamborlane WV. Lipoatrophy associated with lispro insulin in insulin pump therapy: An old complication, a new cause? Diabetes Care 2001: 24: 174.
12. Galloway JA, Root MA, Chance RE, Jacson RL, Wentworth SM, Davidson JA. Recent pharmaceutical developments in insulin preparations -1973. Geigy Symposium Series. New Horizons in the Case of Diabetes Mellitus. 1973: 55-63.
13. Teuscher A. Treatment of insulin lipoatrophy with monocomponent insulin. Diabetologia 1974: 10: 211-214.
14. Wentworth SM, Galloway JA, Davidson JA, Root MA, Chance RE, Haunz EA. An update of results of the use of "single-peak" (SP) and "single-component" (SC) insulins in patients with complications of insulin therapy. Diabetes 1976: 25 (Suppl. 1): 326 (Abstract).
15. Edidin DV. Cutaneous manifestations of diabetes mellitus in children. Pediatr Dermatol 1985: 2: 161-179.
16. Raile K, Noelle V, Landgraf R, Schwarz HP. Insulin antibodies are associated with lipoatrophy but also with lipohypertrophy in children and adolescents with type 1 diabetes. Exp Clin Endocrinol Diabetes 2001: 109: 393-396.
17. Avery H. Insulin fat atrophy: A traumatic atrophic panniculitis. Br Med J 1929: 1: 597.
18. Carmichael EA, Graham G. Local fat atrophy following insulin injections. Lancet 1928: 1: 601.
19. Marble A. Complications of insulin therapy. In: Ellenberg MN, Rifkin H, eds. Diabetes Mellitus: Theory and Practice. New York: McGraw Hill, 1970: 638.
20. Watson D, Vines R. Variations in the incidence of lipodystrophy using different insulins. Med J Aust 1973: 1: 248-250.
21. Renold AE, Winegrad AI, Martin DB. Diabetes mellitus and the adipose tissue. Helv Med Acta 1957: 24: 3227.
22. Lahtela JT, Knip M, Paul R, Antonen J, Salmi J. Antibody-mediated human insulin resistance: Successful treatment with the insulin analog lispro. A case report. Diabetes Care 1997: 20: 71-73.
23. Gerich JE. Novel insulins: Expanding options in diabetes management. Am J Med 2002: 113: 308-316.
24. Heise T, Heinemann L. Rapid and long-acting analogues as an approach to improve insulin therapy: An evidence-based medicine assessment. Curr Pharm Des 2001: 7: 1303-1325.
25. Bolli GB. Physiological insulin replacement in type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes 2001: 109 (Suppl. 2): S317-S332.
26. Slieker LJ, Brooke GS, Di Marchi RD et al. Modifications in the B10 and B26-30 regions of the B chain human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor. Diabetologia 1997: 40 (Suppl. 2): S54-S61.
27. Di Marchi RD, Chance RE, Long HB, Shields JE, Slieker LJ. Preparation of an insulin with improved pharmacokinetics relative to human insulin through consideration of structure homology with insulin-like growth factor I. Horm Res 1994: 41 (Suppl. 2): 93-96.
28. Brems DN, Alter LA, Beckage MJ et al. Altering the association properties of insulin by amino acid replacement. Protein Eng 1992: 5: 527-533.
29. Bolli GB, Di Marchi RD, Pard GD, Pramming S, Koivisto VA. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999: 42: 1151-1167.
30. Arranz A, Andia V, Lopez-Guzman A. A case of lipoatrophy with lispro insulin without insulin pump therapy. Diabetes Care 2004: 27: 625-626.
31. Ampudia-Blasco FJ, Hasbum B, Carmena R. A new case of lipoatrophy with lispro insulin pump therapy: Is there any insulin preparation free of complications? Diabetes Care 2003: 26: 953-954.
32. Ampudia-Blasco FJ, Girbes J, Carmena R. A case of lipoatrophy with insulin glargine. Long-acting insulin analogs are not exempt from this complication. Diabetes Care 2005: 28: 2983.
33. Lepore M, Pampanelli S, Faneli C et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000: 49: 2142-2148.
34. Arioglu E, Rother KI, Reitman ML, Premkumar A, Taylor SI. Lipoatrophy syndromes: When 'too little fat' is a clinical problem. Pediatr Diabetes 2000: 1: 155-168.
35. Garg A, Misra A. Lypodystrophies: Rare disorders causing metabolic syndrome. Endocrinol Metab Clin North Am 2004: 33: 305-331.
36. Bressler R, Galloway JA. Insulin treatment of diabetes mellitus. Med Clin North Am 1971: 55: 861-876.
37. Young RJ, Hannan WJ, Frier BM, Steel JM. Diabetic lipohypertrophy delays insulin absorption. Diabetes Care 1984: 7: 479-480.
38. Turner BC, Hejlesen OK, Kerr D, Cavan DA. Impaired absorption and omission of insulin: A novel method of detection using the diabetes advisory system computer model. Diabetes Technol Ther 2001: 3: 99-109.
39. Chisholm DJ, Kraegen EW, Hewett MJ, Furler S. Low subcutaneous degradation and slow absorption of insulin in insulin-dependent diabetic patients during continuous subcutaneous insulin infusion at basal rate. Diabetologia 1984: 27: 238-241.
40. Logwin S, Conget I, Jansa M, Vidal M, Nicolau C, Gomis R. Human insulin-induced lipoatrophy. Successful treatment using a jet-injection device. Diabetes Care 1996: 19: 255-256.
41. Whitley TH, Lawrence PA, Smith CL. Amelioration of insulin lipoatrophy by dexamethasone injection. JAMA 1976: 23: 839-840.